BidaskClub lowered shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a hold rating to a sell rating in a research report report published on Wednesday morning, BidAskClub reports.

Several other research firms also recently weighed in on BCRX. HC Wainwright assumed coverage on in a research report on Wednesday, May 22nd. They set a buy rating on the stock. ValuEngine raised Westpac Banking from a sell rating to a hold rating in a research report on Wednesday, May 22nd. Piper Jaffray Companies set a $15.00 price objective on BioCryst Pharmaceuticals and gave the company a buy rating in a research report on Monday, April 22nd. Royal Bank of Canada reaffirmed a buy rating on shares of PrairieSky Royalty in a research report on Friday, May 24th. Finally, JMP Securities cut their price objective on BioCryst Pharmaceuticals from $18.00 to $10.00 and set an outperform rating on the stock in a research report on Thursday, May 23rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of $9.56.

NASDAQ BCRX opened at $3.23 on Wednesday. The company has a market cap of $355.21 million, a P/E ratio of -3.30 and a beta of 2.05. The company has a current ratio of 1.77, a quick ratio of 1.76 and a debt-to-equity ratio of 2.38. The firm’s 50 day moving average is $3.56. BioCryst Pharmaceuticals has a fifty-two week low of $2.80 and a fifty-two week high of $9.95.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.28) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.28). The firm had revenue of $5.89 million for the quarter, compared to the consensus estimate of $2.92 million. BioCryst Pharmaceuticals had a negative return on equity of 223.34% and a negative net margin of 472.12%. On average, research analysts expect that BioCryst Pharmaceuticals will post -1.21 EPS for the current fiscal year.

In other BioCryst Pharmaceuticals news, CFO Thomas R. Staab II sold 9,750 shares of the company’s stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $7.63, for a total value of $74,392.50. Following the completion of the sale, the chief financial officer now directly owns 142,426 shares in the company, valued at approximately $1,086,710.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Thomas R. Staab II sold 7,750 shares of the company’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $7.30, for a total value of $56,575.00. Following the completion of the sale, the chief financial officer now owns 140,426 shares of the company’s stock, valued at $1,025,109.80. The disclosure for this sale can be found here. Insiders sold a total of 67,500 shares of company stock worth $517,223 in the last ninety days. 5.20% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the business. Spark Investment Management LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter worth $392,000. Paloma Partners Management Co purchased a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth $84,000. Bank of New York Mellon Corp lifted its holdings in shares of BioCryst Pharmaceuticals by 29.0% in the 4th quarter. Bank of New York Mellon Corp now owns 543,026 shares of the biotechnology company’s stock worth $4,383,000 after buying an additional 122,201 shares during the period. JGP Global Gestao de Recursos Ltda. lifted its holdings in shares of BioCryst Pharmaceuticals by 8.5% in the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 25,742 shares of the biotechnology company’s stock worth $210,000 after buying an additional 2,018 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 69.7% in the 4th quarter. Principal Financial Group Inc. now owns 30,180 shares of the biotechnology company’s stock worth $244,000 after buying an additional 12,400 shares during the period. Institutional investors and hedge funds own 91.96% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Featured Story: What does a bar chart display?

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.